FranΓ§aisπ See the interactive version (live chart) β
For Encompass Health, we replayed every analyst price target of the past 12 months and measured the real outcome: 58% were profitable, average return +16% (112 calls). At 3 months: +2% average return (35% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Credit Suisse | 15 | 53% | +12% |
| Raymond James | 15 | 53% | +13% |
| RBC Capital | 13 | 69% | +22% |
| Truist Securities | 12 | 67% | +21% |
| Barclays | 11 | 73% | +20% |
Is Encompass Health overvalued, and is it a good time to buy Encompass Health right now? If you're wondering, here's a recap to make up your own mind: Encompass Health's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Encompass Health | Sector median (Health Care) |
|---|---|---|
| P/E | 20.2 | 29.4 |
| Forward P/E | 17.9 | 17.1 |
| Net margin | 10% | 12% |
π Encompass Health trades below its sector median (20.2 vs 29.4) β potentially undervalued, or lower expected growth.
π P/E, PEG, marginβ¦: see the glossary
π΅ Dividend : Encompass Health pays about $0.93/share/yr β 0.92% yield. what is this?
The analyst consensus on Encompass Health (EHC) is "Buy" (11 bullish, 0 bearish calls over 12 months). This is not advice: historically, 58% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $147 (+23% vs $120), ranging from $140 to $155 (4 analysts).
Over 1 year, 58% of analyst targets on Encompass Health were profitable, for an average return of +16% (across 112 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $147 within 12 months, i.e. +23% vs the current price. The most bullish targets $155, the most cautious $140.
Note: analyst targets are 12-month (median $147, +23%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (58%), and the stock's past trajectory.
Its P/E is 20.2, forward P/E 17.9. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Encompass Health β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.